2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Tiffany A. Traina, MD, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.
Tiffany A. Traina, MD, medical oncologist, vice chair, Oncology Care, Department of Medicine, section head, Triple Negative Breast Cancer Clinical Research Program, Memorial Sloan Kettering Cancer Center, discusses the implications of the phase 3 DESTINY-Breast03 trial (NCT03529110) in HER2-positive breast cancer.
The 1:1 randomized trial examined the safety and efficacy of the antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), vs ado-trastuzumab emtansine (Kaycyla; T-DM1) in the second line and later in patients with HER2-positive metastatic breast cancer, Traina explains. Results demonstrated trastuzumab deruxtecan elicited significantly higher overall response rates (ORRs) compared with T-DM1, Traina adds. Trastuzumab deruxtecan achieved an ORR of 79.7%.
Additionally, the median progression free survival (PFS) was not reached for patients in the trastuzumab deruxtecan group, and the median PFS was 6.8 months for the T-DM1 group, Traina continues. Notably, overall survival data remains immature, but the follow-up presentations are anticipated, Traina concludes